TD Asset Management Inc Acquires Shares of 18,000 NewAmsterdam Pharma Company N.V. $NAMS

TD Asset Management Inc acquired a new stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 18,000 shares of the company’s stock, valued at approximately $512,000.

A number of other hedge funds have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in NewAmsterdam Pharma in the 1st quarter valued at $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in NewAmsterdam Pharma by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock worth $5,898,000 after purchasing an additional 34,563 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in NewAmsterdam Pharma in the second quarter valued at $212,000. Bank of New York Mellon Corp acquired a new position in NewAmsterdam Pharma in the second quarter valued at $6,392,000. Finally, Geode Capital Management LLC raised its holdings in shares of NewAmsterdam Pharma by 15.9% in the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock valued at $1,800,000 after buying an additional 13,629 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Down 0.9%

Shares of NASDAQ:NAMS opened at $29.86 on Friday. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00. The company has a 50-day moving average price of $33.57 and a 200 day moving average price of $33.15. The company has a market cap of $3.43 billion, a P/E ratio of -17.26 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. Analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson sold 443,707 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the sale, the chief executive officer owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 45,481 shares of the business’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $35.31, for a total transaction of $1,605,934.11. Following the sale, the insider owned 53,500 shares in the company, valued at $1,889,085. The trade was a 45.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,094,128 shares of company stock worth $37,170,889 over the last three months. 20.84% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

NAMS has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. The Goldman Sachs Group boosted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. Wall Street Zen cut NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Leerink Partners reiterated an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $47.10.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.